Sepracor, Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, has focused their efforts on treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products designed to serve large and growing markets. The company’s drug development program has proven its success by yielding a portfolio of pharmaceutical products and candidates. The focus of the program is on treating respiratory and central nervous system (CNS) disorders. For further information, visit the Company’s web site at www.sepracor.com.
- 17 years ago
QualityStocks
Sepracor, Inc. (NASDAQ: SEPR)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…